



WA STATE PERTUSSIS UPDATE December 5, 2024

Before We Start

- All participants will be muted for the presentation.
- You may ask questions using the Q&A box, and questions will be answered at the end of the presentation.
- Continuing education is available for nurses, medical assistants, and pharmacists/pharmacy techs.
- If you're watching in a group setting and wish to claim CE credit, please make sure you register for the webinar and complete the evaluation as an individual.
- You can find more information here: <u>https://doh.wa.gov/you-and-your-family/immunization/immunization-training/pertussis-updates-December-5</u>

Continuing Education

- This nursing continuing professional development activity was approved by Montana Nurses Association, an accredited approver with distinction by the American Nurses Credentialing Center's Commission on Accreditation. Upon successful completion of this activity, 1.0 contact hours will be awarded.
- This program has been granted prior approval by the American Association of Medical Assistants (AAMA) for 1.0 administrative continuing education unit.
- This knowledge activity was approved by the Washington State Pharmacy Association for 1.0 contact hours. The Washington State Pharmacy Association is accredited by the Accreditation Council for Pharmacy Education as a Provider of continuing pharmacy education.



Disclosures

The planners and speakers of this activity have no relevant financial relationships with any commercial interests pertaining to this activity.

Learning Objectives

•Describe pertussis clinical manifestation, treatment, and vaccine recommendations

- •Discuss vaccination coverage in Washington State
- •Describe pertussis surveillance and reporting guidelines

Presenters

Conor Nath, MD Resident, University of Washington Department of Pediatrics Seattle Children's

Kaitlyn Sykes, MPH Office of Immunization Washington State Department of Health

Esther Lam, MPH Office of Communicable Disease Epidemiology Washington State Department of Health

Pertussis Clinical Manifestations


CONOR NATH, MD


Pertussis, Whooping Cough

- Pertussis, also known as whooping cough
- Primarily a toxin-mediated disease
- Toxins damage the lining of the respiratory tract
 - interferes with the clearing of pulmonary secretions
 - Can cause inflammation within the airway
- Results in intermittent, violent coughing spells
- Inhaling (gasping) through inflamed airways results in the characteristic "whooping" sound
- The cough can last for months "the 100-day cough"



Incubation and disease progression





Variations to Characteristic Features

Adolescents, adults, and vaccinated children

- Persistent cough
- Milder disease
- Inspiratory whoop uncommon
- May still transmit the disease to other susceptible persons

Complications: Children, Adolescents and Adults

- Nose bleeds
- Urinary incontinence
- Rib fracture
- Syncope (fainting)

- Pneumothorax (collapsed lung)
- Rectal prolapse
- Subdural hematomas (a type of

bleeding in the brain)

- Seizures
- Encephalopathy

Pneumonia

Infant Presentation

Most severe in those under 12 months and in preterm or unimmunized infants

- May not cough or may be minimal
- Absence of the characteristic "whoop"
- Exhaustion
- Struggle to breathe
- Cyanosis
- Apnea (May be the only symptom)



Infants may not have classic symptoms and only present with apnea.

Testing

Culture


- Gold standard, 100% specific for identification
- Best within 2 weeks from cough onset (after 2 weeks, risk of false negative increases)
- Allows for strain identification and antimicrobial susceptibilities (especially helpful during outbreaks)

• PCR (polymerase chain reaction)

- Most rapid test available
- Use up to 3-4 weeks following cough onset
- High sensitivity; risk of false positivity

Serology testing

• Not recommended in Washington State



• Widely available at commercial, hospital, and clinical labs

Medical Management & Preventive Measures

- Primarily Supportive
- If administered early, antibiotics can be helpful
 - 5-day course of azithromycin
 - Catarrhal phase
 - Antibiotics eradicate the organism from secretions
 - Decrease communicability
 - May lessen symptoms or shorten duration of disease
- Give before test results if clinical history is highly suggestive or the patient is at high risk for complications

Post-exposure Prophylaxis

Given to ...

Close contacts

- Living in the same household
- Face-to-face exposure within 3 feet of a symptomatic patient
- Direct contact with respiratory, oral, or nasal secretions from a symptomatic patient
- Sharing the same confined space in close proximity with a symptomatic patient for ≥1 hour

High risk individuals

- Infants younger than one year, or those in contact with infants <1 year old
- Pregnant persons
- People with underlying immunodeficiencies or chronic medical conditions.

Recommended Antimicrobial Agents for the Treatment and Postexposure Prophylaxis of Pertussis

Age	Recommended Drugs			Alternative
	Azithromycin	Erythromycin	Clarithromycin	TMP-SMX
Younger than 1 mo	10 mg/kg/day as a single dose daily for 5 days ^{<u>b</u>,c}	40 mg/kg/day in 4 divided doses for 14 days	Not recommended	Contraindicated at younger than 2 mo
1 through 5 mo	10 mg/kg/day as a single dose daily for 5 days ^{<u>b</u>}	40 mg/kg/day in 4 divided doses for 14 days	15 mg/kg/day in 2 divided doses for 7 days	2 mo or older: TMP, 8 mg/kg/day; SMX, 40 mg/kg/day in 2 doses for 14 days
6 mo or older and children	10 mg/kg as a single dose on day 1 (maximum 500 mg), then 5 mg/kg/day as a single dose on days 2 through 5 (maximum 250 mg/day) ^{<u>b</u>,<u>d</u>}	40 mg/kg/day in 4 divided doses for 7-14 days (maximum 2 g/day)	15 mg/kg/day in 2 divided doses for 7 days (maximum 1 g/day)	2 mo or older: TMP, 8 mg/kg/day; SMX, 40 mg/kg/day in 2 doses for 14 days
Adolescents and adults	500 mg as a single dose on day 1, then 250 mg as a single dose on days 2 through 5 <mark>b,d</mark>	2 g/day in 4 divided doses for 7-14 days	1 g/day in 2 divided doses for 7 days	TMP, 320 mg/day; SMX, 1600 mg/day in 2 divided doses for 14 days

https://www.cdc.gov/mmwr/previe w/mmwrhtml/rr5414a1.htm

Vaccine Recommendations

Vaccination is the Best Protection

Whooping Cough **Vaccinate To Protect** Who Needs Whooping Cough Vaccines? Pregnant women Infants and young children Preteens and teens Adults of all ages Whooping cough is most deadly for infants. Get vaccinated. Protect yourself. Protect babies.


https://www.cdc.gov/vaccines/pubs/pinkbook/pert.html Washington State Department of Health | 18 Available DTaP and Tdap Vaccines

Pertussis-containing Vaccines

- DTaP (Daptacel and Infanrix)
- Tdap (Adacel and Boostrix)
- DTaP-HepB-IPV (Pediarix)
- DTaP-IPV/Hib (Pentacel)
- DTaP-IPV (Kinrix and Quadracel)
- DTaP-IPV-Hib-HepB (Vaxelis)

<u>Chapter 16: Pertussis | Pink Book | CDC</u> <u>Types of Whooping Cough Vaccines | Whooping</u> <u>Cough | CDC</u>

DTaP and Tdap Vaccine Recommendations



About Whooping Cough | Whooping Cough | CDC

Adults should get a booster dose of Td or Tdap every 10 years to maintain protection.

Adults and caregivers should receive Tdap to protect vulnerable babies from pertussis in the first few months of life.



About Whooping Cough | Whooping Cough | CDC

Additional Notes

- Vaccines are the best way to protect against pertussis
- Vaccination protects against serious disease if person gets pertussis
- Pertussis vaccines work well but protection fades over time
- Tdap vaccination during pregnancy protects:
 - More than 3 in 4 babies younger than 2 months from pertussis
 - About 9 in 10 babies from being hospitalized
- Review patient history prior to vaccinating
- Review WAIIS forecast

Resources

- <u>Recommended Child and Adolescent Immunization Schedule for</u> ages 18 years or younger; 2024 U.S. (cdc.gov)
- <u>Catch-Up Guidance for Children 4 Months through 6 Years of Age</u> Vaccines: DTap, December 2023 (cdc.gov)
- <u>2024: Tetanus, Diphtheria, and Pertussis-Containing Vaccines--</u> <u>Catch-up Guidance for Children 7 through 9 years of age (cdc.gov)</u>
- <u>2024: Tetanus, Diphtheria, and Pertussis-Containing Vaccines--</u> <u>Catch-up Guidance for Children 10 through 18 years of age</u> (cdc.gov)
- <u>Communication and Print Resources | CDC</u>
- <u>Ask The Experts: Pertussis | Immunize.org</u>
- <u>Pertussis (Whooping Cough) | Whooping Cough | CDC</u>
- Clinical questions: <u>immunenurses@doh.wa.gov</u>



About Whooping Cough | Whooping Cough | CDC

Knowledge Check

- 1. Infants often don't present with the classic pertussis symptoms, what symptom might they present with instead?
- 2. What groups of people would be eligible for post-exposure prophylaxis?

Knowledge Check Answers

- 1. Infants often only present with symptoms of apnea
- Groups eligible for post-exposure prophylaxis include: Close contacts and individuals at high risk of complications

Pertussis Immunization Coverage in Washington

KAITLYN SYKES, MPH

Pertussis Immunization Coverage in Washington



Pertussis Immunization Coverage for Children 19-35 Months: WAIIS-Based Data

WAIIS Immunization Coverage Data


Applications


- Use to assess statewide vaccination coverage as well as geographic and demographic variation
- Provides continuous near real-time updates

Limitations

- IIS denominator inflation results in underestimates
- Race and ethnicity data are based on provider report to WAIIS
- Coverage estimates for earlier time periods can change over time. IIS is an 'in the moment' registry

Statewide Immunization Coverage Trends Among 19-35 Month-Olds, 2015 to 2023







DTaP administrations among 2-3 year olds, 2015 to 2023

Washington State Department of Health | 30


4+ Dtap coverage among 19-35 month olds, 2015 to 2023




DTaP administrations among 4-6 year olds, 2015 to 2023



5+ DTaP coverage among 4-6 year olds, 2015 to 2023



Statewide DTaP Coverage Trends Among 19-35 Month-Olds by County, 2023



Pertussis Immunization Data for the K-12 Population: Washington School Reports

Data Collection

- State law requires all public and private schools with any students in grades K through 12 to submit an Immunization Status Report by December 1 of each school year.
 - Submit data in WAIIS School Module or through a REDCap report.


Applications

- Used to assess school and district-level vaccination status
- Provides accurate school-level vaccine coverage data on annual basis

Limitations


- Specific to school-going population
- Limited grade levels and demographics
- Single update at end of year

Pertussis Immunization Compliance by Grade Cohort




School Immunization Data:

K-12 Pertussis Immunization Status – Non-Compliant




School Immunization Data – K-12 County Level



School Immunization Data – K-12 School District Level

% Complete 95.1-100 90.1-95.0 85.1-90.0 80.1-85.0 0.0-80.0 NA



Thank you!

Data can be found on DOH immunization dashboards: Immunization Measures by County Dashboard School Immunization Data Dashboard

Questions or data requests can be sent to: <u>waiisdatarequests@doh.wa.gov</u>

Pertussis Surveillance Update

ESTHER LAM, MPH

Surveillance

Pertussis

1. DISEASE REPORTING

A. Purpose of Reporting and Surveillance

- 1. To prevent illness and death, particularly among infants younger than 1 year, and among persons who may transmit pertussis to infants.
- 2. To limit transmission of pertussis in settings with infants or others who may transmit pertussis to infants.
- 3. To monitor the epidemiology of pertussis in Washington state.

B. Legal Reporting Requirements

- 1. Health care providers and facilities: notifiable to local health jurisdiction within 24 hours.
- 2. Laboratories: *Bordetella pertussis* notifiable to local health jurisdiction within 24 hours; submission of culture isolates required, when available (2 business days).

Criteria used for classifying pertussis cases

Clinical case definition

A cough illness lasting at least 2 weeks, with at least one of the following:

- Paroxysms of coughing
- Inspiratory whoop
- Post-tussive vomiting
- Apnea

Laboratory diagnostics

- A positive bacterial culture for *B. pertussis*
- Positive PCR test for *B. pertussis*


Serology is not considered a valid test for surveillance purposes.

Please note!

All data presented in the following slides is preliminary and subject to change. Some cases are still under investigation.


Monthly Case Counts: 10 years of context

Figure 2: WA State Pertussis Cases Reported by Month and Year (black) with Projected Baseline and Epidemic Thresholds (red dashed lines), 2014 through year-to-date 2024¹. *The most recent 2 months may still be incomplete (dotted line).*



Weekly pertussis case counts, through 11/23/2024 (week 47) 1,533 cases compared to by the same week in 2023

Figure 1: Number of Pertussis Cases Reported in Washington State by CDC Week of Symptom Onset: 2023 (blue) vs 2024 (red)



Washington State Department of Health | 47

Ages of Confirmed and Probable Pertussis Cases

Table 1: WA State Pertussis Cases	by Age Group, 2024 weeks 1 - 47
-----------------------------------	---------------------------------

Age Group	OFM 2022 Population	Number of Cases	Rate per 100,000 persons	% of cases by age group*
< 1	88,441	144	162.8	9
1 - 4	349,505	316	90.4	21
5 - 9	476,054	262	55.0	17
10 - 13	396,426	181	45.7	12
14 - 18	480,566	355	73.9	23
19 - 24	588,771	121	20.6	8
25 - 44	2,225,672	92	4.1	6
45 - 64	1,911,375	44	2.3	3
65+	1,347,568	18	1.3	1
All ages	7,864,378	1,533	19.5	100

*Due to rounding, percentages may not always add up to 100%

Ages of Confirmed and Probable Pertussis Cases

Age Group	OFM 2022 Population	Number of Cases	Rate per 100,000 persons	% of cases by age group*
< 1	88,441	144	162.8	9
1 - 4	349,505	316	90.4	21
5 - 9	476,054	262	55.0	17
10 - 13	396,426	181	45.7	12
14 - 18	480,566	355	73.9	23
19 - 24	588,771	121	20.6	8
25 - 44	2,225,672	92	4.1	6
45 - 64	1,911,375	44	2.3	3
65+	1,347,568	18	1.3	1
All ages	7,864,378	1,533	19.5	100

*Due to rounding, percentages may not always add up to 100%

Ages of Confirmed and Probable Pertussis Cases

School age children: 798 cases, 52%

 Table 1: WA State Pertussis Cases by Age Group, 2024 weeks 1 - 47

Age Group	OFM 2022 Population	Number of Cases	Rate per 100,000 persons	% of cases by age group*
< 1	88,441	144	162.8	9
1 - 4	349,505	316	90.4	21
5 - 9	476,054	262	55.0	17
10 - 13	396,426	181	45.7	12
14 - 18	480,566	355	73.9	23
19 - 24	588,771	121	20.6	8
25 - 44	2,225,672	92	4.1	6
45 - 64	1,911,375	44	2.3	3
65+	1,347,568	18	1.3	1
All ages	7,864,378	1,533	19.5	100

*Due to rounding, percentages may not always add up to 100%

Hospitalization (under 1)

Hospitalized at least overnight for pertussis?	n	%
Yes	13	9.0%
No	130	90.3%
Missing (not yet completed)	1	0.7%
Total	144	

Of the 13 hospitalized infants:

- None were known to have been born to a person who had received Tdap during this pregnancy
- Only one had received any doses of pertussis-containing vaccine (8%)
- Three were old enough to have received one or more doses (23%)

Of the other 131 infants (non-hospitalized or missing hospitalization):

• 21 had received at least one dose of vaccine (16%)

Hospitalization (all ages)

Hospitalized at least overnight for pertussis?	n	%	
Yes	3	0	2.0%
No	1,48	5	96.8%
Unknown		3	0.2%
Missing	1	5	1.0%
Total	1,53	3	

Only 10 hospitalized patients were known to have ever received a documented dose of pertussis-containing vaccine (33%).

Summary

- More than half of cases were among school-aged children (5 18 years old).
 - All school-aged children were born when only acellular pertussis vaccine was available.
 - K-12 schools may be a key setting for the transmission of pertussis in WA in 2024.
- A high percentage of pertussis cases have been reported among children 1 to 4 years old.
 - Most of these children were born since 2020, when routine pertussis immunization coverage decreased.
- Most hospitalized patients had no documented history of pertussis vaccination.

Knowledge Check

Pertussis cases are rising in all age groups but the majority of cases are among one group. Which group: infants, school aged, or adults?

Knowledge Check Answer

More than half of the cases are among school-aged children (5 - 18 years old). K-12 schools may be a key setting for the transmission of pertussis in WA in 2024.

Thank you!

Weekly Pertussis surveillance report can be found at: <u>https://doh.wa.gov/sites/default/files/legacy/Documents/Pubs/348-254-PertussisUpdate.pdf</u>

Questions?

Contact: vpd-cde@doh.wa.gov

Obtaining Continuing Education

•Continuing education credit is available for nurses, medical assistants, and pharmacists/pharmacy techs

- •There is no cost for CEs
- •Expiration date is 3/5/25
- •Successful completion of this continuing education activity includes the following:
 - Attending the entire live webinar or watching the webinar recording, and completing the evaluation
 - On the evaluation, please specify which type of continuing education you wish to obtain

•Please note: CE certificates are NOT generated after evaluation completion—CE certificates will be sent by DOH via email within a few weeks after evaluation completion

•If you have any questions about CEs, contact Trang Kuss at trang.kuss@doh.wa.gov

Evaluation QR code https://www.surveymonkey.com/ r/YXDDRBX





To request this document in another format, call 1-800-525-0127. Deaf or hard of hearing customers, please call 711 (Washington Relay) or email civil.rights@doh.wa.gov. To request this document in another format, call 1-800-525-0127. Deaf or hard of hearing customers, please call 711 (Washington Relay) or email civil.rights@doh.wa.gov.